drugset
drugset / Trial / NCT06537817

Study to Evaluate HT-4253 in Healthy Subjects

NCT06537817 ↗

Phase 1 Completed 80 enrolled Halia Therapeutics, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects. The secondary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of HT-4253.

Timeline

Start
2024-09-17
Primary completion
2025-05-12
Completion
2025-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HT-4253 Unknown — Oral

Indications

No indication recorded.